#1 Clinical Trials Search in Europe

Frexalimab

Frexalimab is an experimental drug currently being studied in clinical trials for various autoimmune conditions. These trials aim to evaluate the safety and effectiveness of Frexalimab in treating diseases such as multiple sclerosis, type 1 diabetes, and certain kidney disorders. Researchers are investigating how this new medication might help manage symptoms, slow disease progression, and improve patients’ quality of life.

Table of Contents

What is Frexalimab?

Frexalimab is a new medication currently being studied for its potential to treat several autoimmune conditions[1][2][3][4]. It is classified as a CD40L-antagonist monoclonal antibody. To break this down:

  • Monoclonal antibody: This is a type of protein made in a laboratory that can bind to specific substances in the body. In this case, it’s designed to target a specific part of the immune system.
  • CD40L-antagonist: This means it blocks (or antagonizes) a molecule called CD40L, which plays a role in immune system activation.

What Conditions Does Frexalimab Treat?

Frexalimab is being investigated for several autoimmune conditions, where the immune system mistakenly attacks the body’s own tissues. These include:

  • Type 1 Diabetes: A condition where the immune system attacks the insulin-producing cells in the pancreas[1].
  • Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD): These are kidney disorders that affect the filtering units of the kidneys[2].
  • Multiple Sclerosis (MS): A disease of the central nervous system where the immune system attacks the protective covering of nerves[3][4].

How Does Frexalimab Work?

Frexalimab works by targeting a specific part of the immune system. It blocks the CD40L molecule, which is involved in activating certain immune cells. By doing this, it may help to reduce the overactive immune response seen in autoimmune diseases[1].

In Type 1 Diabetes, for example, researchers are studying whether Frexalimab can help preserve the function of insulin-producing cells in the pancreas[1]. In Multiple Sclerosis, the hope is that it can slow down the progression of disability and reduce the frequency of relapses[3][4].

How is Frexalimab Administered?

Based on the clinical trials, Frexalimab is typically given in two ways[1][3][4]:

  • Intravenous (IV) infusion: This is usually given at the start of treatment. An IV infusion means the medication is given directly into a vein.
  • Subcutaneous (SC) injection: After the initial IV infusion, the medication may be given as an injection under the skin.

The frequency and duration of treatment can vary depending on the condition being treated and the specific clinical trial protocol.

Current Clinical Trials

Frexalimab is currently being studied in several clinical trials:

  • A Phase 2b study in Type 1 Diabetes, lasting up to 104 weeks[1].
  • A Phase 2a study in FSGS and MCD, lasting 24 weeks[2].
  • A Phase 3 study in non-relapsing Secondary Progressive Multiple Sclerosis, lasting up to 51 months[3].
  • Two Phase 3 studies in relapsing forms of Multiple Sclerosis, lasting up to 40 months[4].

Potential Benefits of Frexalimab

While the full benefits of Frexalimab are still being studied, researchers are looking at several potential positive outcomes:

  • In Type 1 Diabetes: Preservation of insulin-producing cell function, which could lead to better blood sugar control[1].
  • In FSGS and MCD: Reduction in protein in the urine, which is a sign of improved kidney function[2].
  • In Multiple Sclerosis: Slowing of disability progression, reduction in relapse rates, and improvement in brain MRI measures[3][4].

Possible Side Effects and Safety Considerations

As with all medications, Frexalimab may cause side effects. The full safety profile is still being determined through clinical trials. Researchers are closely monitoring for[1][2][3][4]:

  • Adverse events (any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of the medication)
  • Serious adverse events
  • Changes in vital signs, electrocardiogram (ECG) readings, and laboratory test results
  • Development of anti-drug antibodies (when the body’s immune system produces antibodies against the medication)

In the Multiple Sclerosis trials, specific attention is being paid to the risk of infections, as the medication affects the immune system[3][4].

It’s important to note that Frexalimab is still an experimental medication. Its safety and effectiveness must be fully established through clinical trials before it can be approved for general use. Patients considering participating in a clinical trial should discuss the potential risks and benefits with their healthcare provider.

Condition Trial Phase Key Outcomes Measured Administration Method
Type 1 Diabetes Phase 2b C-peptide levels, Time in range for blood glucose, Insulin dose changes IV infusion and SC injection
Focal Segmental Glomerulosclerosis and Minimal Change Disease Phase 2a Reduction in urine protein to creatinine ratio, Remission rates Not specified in data
Secondary Progressive Multiple Sclerosis Phase 3 Time to disability progression, Brain volume loss, Cognitive function IV infusion
Relapsing Forms of Multiple Sclerosis Phase 3 Annualized relapse rate, Disability progression, New brain lesions IV infusion

FAQ

  • What is Frexalimab? Frexalimab is an experimental drug being tested in clinical trials. It is a CD40L-antagonist monoclonal antibody, which means it targets a specific part of the immune system to potentially reduce inflammation and autoimmune responses.
  • What conditions is Frexalimab being studied for? Frexalimab is currently being studied for multiple sclerosis (including relapsing and secondary progressive forms), type 1 diabetes, and kidney disorders such as focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
  • How is Frexalimab administered in these trials? In the trials, Frexalimab is typically administered through intravenous (IV) infusion and/or subcutaneous (SC) injection. The specific dosing schedule varies depending on the study and condition being treated.
  • What are the main goals of these Frexalimab clinical trials? The main goals of these trials are to assess the safety of Frexalimab and its effectiveness in treating various conditions. Researchers are looking at outcomes such as disease progression, relapse rates, changes in specific symptoms, and quality of life measures.
  • How long do these clinical trials last? The duration of the trials varies, but they generally last between 24 weeks to 104 weeks (2 years), with some studies including additional follow-up periods. The exact length depends on the specific trial and condition being studied.

Ongoing Clinical Trials on Frexalimab

  • Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

    Recruiting

    4 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +6

  • A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Spain

  • Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +7

  • Study on Frexalimab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Germany Spain

  • Study on Frexalimab for Treating Active Systemic Lupus Erythematosus in Patients

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Spain

  • Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Croatia Czechia Denmark France +10

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In the case of Frexalimab, it's designed to target specific parts of the immune system.
  • CD40L-antagonist: A substance that blocks the action of CD40L, a protein involved in immune system responses. By blocking this, Frexalimab may help reduce inflammation and autoimmune reactions.
  • Type 1 Diabetes Mellitus: An autoimmune condition where the body's immune system attacks and destroys insulin-producing cells in the pancreas, leading to high blood sugar levels.
  • Multiple Sclerosis: A chronic disease affecting the central nervous system, where the immune system mistakenly attacks the protective covering of nerve fibers.
  • Focal Segmental Glomerulosclerosis (FSGS): A type of kidney disease that causes scarring in parts of the kidney's filtering units (glomeruli), leading to kidney damage and potential failure.
  • Minimal Change Disease (MCD): A kidney disorder that causes large amounts of protein to leak into the urine, potentially leading to swelling and other complications.
  • C-peptide: A substance produced along with insulin by the pancreas. Measuring C-peptide levels helps assess how much insulin a person's body is producing.
  • HbA1c: Also known as glycated hemoglobin, this is a measure of average blood sugar levels over the past 2-3 months.
  • Urine protein to creatinine ratio (UPCR): A test that measures the amount of protein in urine compared to creatinine, used to assess kidney function and damage.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Annualized relapse rate (ARR): The number of relapses a person with multiple sclerosis experiences per year, used to assess disease activity and treatment effectiveness.
  • Neurofilament light chain (NfL): A protein released into the blood when nerve cells are damaged, used as a marker of disease activity in conditions like multiple sclerosis.

References